Tags

Type your tag names separated by a space and hit enter

Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer.
Int J Cancer. 2014 Nov 15; 135(10):2453-61.IJ

Abstract

Different human papillomavirus (HPV) genes are expressed during the various phases of the HPV life cycle and may elicit immune responses in the process towards malignancy. To evaluate their association with cervical cancer, antibodies against proteins from HPV16 (L1, E1, E2, E4, E6 and E7) and HPV18/31/33/35/45/52/58 (L1, E6 and E7) were measured in serum of 307 invasive cervical cancer cases and 327 controls from Algeria and India. Antibody response was evaluated using a glutathione S-transferase-based multiplex serology assay and HPV DNA detected from exfoliated cervical cells using a GP5+/6+-mediated PCR assay. Among HPV16 DNA-positive cases, seroprevalence of HPV16 antibodies ranged from 16% for HPV16 E1 to 50% for HPV16 E6 and all were significantly higher than controls. Seroprevalence of E6, E7 and L1 antibodies for HPV18 and for at least one of HPV31/33/35/45/52/58 were also higher in cases positive for DNA of the corresponding type (50% and 30% for E6 of HPV18 and HPV31/33/35/45/52/58 combined, respectively). E6 and E7 antibodies were rarely found in controls, but cross-reactivity was evident among cancer cases positive for DNA of closely phylogenetically-related HPV types. E6 or E7 antibodies against any of the eight HPV types were detected in 66.1% of all cervical cancer cases, as compared to 10.1% of controls. E6, and to a lesser extent E7, antibodies appear to be specific markers of HPV-related malignancy. However, even among cases positive for the same type of HPV DNA, approximately one-third of cervical cancer cases show no detectable immune response to either E6 or E7.

Authors+Show Affiliations

International Agency for Research on Cancer, F-69372, Lyon, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24729277

Citation

Combes, Jean-Damien, et al. "Antibodies Against High-risk Human Papillomavirus Proteins as Markers for Invasive Cervical Cancer." International Journal of Cancer, vol. 135, no. 10, 2014, pp. 2453-61.
Combes JD, Pawlita M, Waterboer T, et al. Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. Int J Cancer. 2014;135(10):2453-61.
Combes, J. D., Pawlita, M., Waterboer, T., Hammouda, D., Rajkumar, T., Vanhems, P., Snijders, P., Herrero, R., Franceschi, S., & Clifford, G. (2014). Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. International Journal of Cancer, 135(10), 2453-61. https://doi.org/10.1002/ijc.28888
Combes JD, et al. Antibodies Against High-risk Human Papillomavirus Proteins as Markers for Invasive Cervical Cancer. Int J Cancer. 2014 Nov 15;135(10):2453-61. PubMed PMID: 24729277.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer. AU - Combes,Jean-Damien, AU - Pawlita,Michael, AU - Waterboer,Tim, AU - Hammouda,Doudja, AU - Rajkumar,Thangarajan, AU - Vanhems,Philippe, AU - Snijders,Peter, AU - Herrero,Rolando, AU - Franceschi,Silvia, AU - Clifford,Gary, Y1 - 2014/04/26/ PY - 2013/12/20/received PY - 2014/03/13/revised PY - 2014/03/21/accepted PY - 2014/4/15/entrez PY - 2014/4/15/pubmed PY - 2014/11/19/medline KW - antibodies KW - case-control study KW - cervical cancer KW - human papillomavirus SP - 2453 EP - 61 JF - International journal of cancer JO - Int. J. Cancer VL - 135 IS - 10 N2 - Different human papillomavirus (HPV) genes are expressed during the various phases of the HPV life cycle and may elicit immune responses in the process towards malignancy. To evaluate their association with cervical cancer, antibodies against proteins from HPV16 (L1, E1, E2, E4, E6 and E7) and HPV18/31/33/35/45/52/58 (L1, E6 and E7) were measured in serum of 307 invasive cervical cancer cases and 327 controls from Algeria and India. Antibody response was evaluated using a glutathione S-transferase-based multiplex serology assay and HPV DNA detected from exfoliated cervical cells using a GP5+/6+-mediated PCR assay. Among HPV16 DNA-positive cases, seroprevalence of HPV16 antibodies ranged from 16% for HPV16 E1 to 50% for HPV16 E6 and all were significantly higher than controls. Seroprevalence of E6, E7 and L1 antibodies for HPV18 and for at least one of HPV31/33/35/45/52/58 were also higher in cases positive for DNA of the corresponding type (50% and 30% for E6 of HPV18 and HPV31/33/35/45/52/58 combined, respectively). E6 and E7 antibodies were rarely found in controls, but cross-reactivity was evident among cancer cases positive for DNA of closely phylogenetically-related HPV types. E6 or E7 antibodies against any of the eight HPV types were detected in 66.1% of all cervical cancer cases, as compared to 10.1% of controls. E6, and to a lesser extent E7, antibodies appear to be specific markers of HPV-related malignancy. However, even among cases positive for the same type of HPV DNA, approximately one-third of cervical cancer cases show no detectable immune response to either E6 or E7. SN - 1097-0215 UR - https://www.unboundmedicine.com/medline/citation/24729277/Antibodies_against_high_risk_human_papillomavirus_proteins_as_markers_for_invasive_cervical_cancer_ L2 - https://doi.org/10.1002/ijc.28888 DB - PRIME DP - Unbound Medicine ER -